Online First
  • Review|Open Access

    Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

    Nele Van Der Steen , Elisa Giovannetti , Daniela Carbone , Alessandro Leonetti , Christian D. Rolfo , Godefridus J. Peters
    Aberrant activation of the epidermal growth factor receptor (EGFR) is a driving force for cancer growth in a subgroup of non-small cell lung cancer patients. These patients can be identified by the presence of activating EGFR mutations. Currently three generations of EGFR-tyrosine kinase inhibitors (TKI) have been approved by the Food and Drug Administration and European Medicine Agency. This paper reviews the structure of EGFR and the downstream signaling pathways of EGFR and describes the mechanisms of intrinsic and acquired resistance against EGFR-TKIs. These mechanisms include secondary... Read more
    Published on: 29 Sep 2018  | Viewed:400  | Downloaded:54
    +HTML| PDF
Cancer Drug Resistance ISSN 2578-532X (Online)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.